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Disparities and guideline adherence in
drugs of abuse screening in intracerebral
hemorrhage
ABSTRACT
Objective: To characterize the pattern of urine drug screening in a cohort of intracerebral hemor-
rhage (ICH) patients at our academic centers.
Methods: We identified cases of primary ICH occurring from 2009 to 2011 in our academic cen-
ters. Demographic data, imaging characteristics, processes of care, and short-term outcomes
were ascertained. We performed logistic regression to identify predictors for screening and eval-
uated preguideline and postguideline reiteration screening patterns.
Results: We identified 610 patients with primary ICH in 2009–2011; 379 (62.1%) were initially
evaluated at an outside hospital. Overall, 142/610 (23.3%) patients were screened, with 21
positive for cocaine and 3 for amphetamine. Of patients ,55 years of age, only 65/140 (46.4%)
were screened. Black patients,55 years of age were screenedmore than nonblack patients,55
years of age (38/61 [62.3%] vs 27/79 [34.2%]; p 5 0.0009). In the best multivariable model,
age group (p 5 0.0001), black race (p 5 0.4529), first Glasgow Coma Scale score (p 5 0.0492),
current smoking (p , 0.0001), and age group 3 black race (p 5 0.0097) were associated with
screening. Guideline reiteration in 2010 did not improve the proportion ,55 years of age who
were screened: 42/74 (56.8%) were screened before and 23/66 (34.9%) after (p 5 0.01).
Conclusions: We found disparities in drugs of abuse (DOA) screening and suboptimal guideline
adherence. Systematic efforts to improve screening for DOA are warranted. Improved identifica-
tion of sympathomimetic exposure may improve etiologic classification and influence decision-
making and prognosis counseling. Neurology® 2017;88:252–258
GLOSSARY
AHC 5 academic health centers; CI 5 confidence interval; DOA 5 drugs of abuse; GCS 5 Glasgow Coma Scale; ICD-9 5
International Classification of Diseases–9; ICH5 intracerebral hemorrhage; INPC5 Indiana Network for Patient Care; IVH5
intraventricular hemorrhage; NIHSS 5 NIH Stroke Scale; NSDUH 5 National Survey on Drug Use and Health; OR 5 odds
ratio; OSH 5 outside hospital; UDS 5 urine drug screen.
Substance abuse is increasingly detected in stroke populations.1 Intracerebral hemorrhage (ICH)
has the highest morbidity and mortality of all stroke subtypes2 and sympathomimetic drugs have
previously been associated with poorer outcomes in ICH.3 The ICH guidelines in 20074 and
20105 recommended toxicology screening in young or middle-aged patients to detect cocaine
and other sympathomimetic drugs of abuse (DOA), but guideline adherence data are scarce,
particularly outside of academic centers. We therefore sought to characterize the prevalence and
predictors of screening for DOA in our primary ICH cohort as well as the effect of guideline
reiteration on screening patterns.
METHODS Standard protocol approvals, registrations, and patient consents. This study was approved by the Indiana
University institutional review board, the Wishard Hospital review board, and the board of directors of the Indiana Network for Patient
Care (INPC).
We performed a retrospective study of primary ICH in patients presenting to our 2 academic health centers (AHC). We queried all
patients $18 years of age in the INPC database6 (http://www.ihie.org/) between January 1, 2009, and December 31, 2011, with
ICD-9 codes of 431 and 432.9. ICD-9 codes 431 and 432.9 have been demonstrated to have.85% sensitivity for the identification of
patients with ICH.7 The database was additionally queried until February 29, 2012, to identify patients who were admitted to
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a participating hospital during the study period but discharged
from the hospital in the following months. A vascular neurologist
(J.M.) reviewed the entire chart and imaging scans of all potential
cases to ensure correct case ascertainment. Patients with suspected
ICH etiologies of trauma, aneurysm, encephalitis, or tumor were
excluded. Patients with suspected hemorrhagic transformation of
an ischemic infarct or hemorrhage due to venous sinus thrombo-
sis, carotid endarterectomy, or thrombolytic administration for
ischemic stroke were also excluded.
Abstractors ascertained via chart review demographic data,
vascular risk factors (including hypertension, diabetes mellitus,
history of smoking, and dyslipidemia), and other comorbidities
including modified Charlson score and process of care variables
under the close supervision of the vascular neurologist. All clinical
data were recorded in Research Electronic Data Capture
(REDCap).8 Referring hospital data and all transfer data were
reviewed. If an NIH Stroke Scale (NIHSS) score was not explic-
itly calculated, we used a validated method to estimate NIHSS.9
The neurologist reviewed the initial imaging scan from the
academic center as well as the initial imaging scan from the
referring hospital, if available. Hematoma volume was calculated
via the ABC/2 method10 and the intraventricular volume was
calculated via a previously reported method.11
We ascertained whether urine drug screen (UDS) was
performed as well as results for cocaine or amphetamine/
methamphetamine at both the referring hospitals and academic
centers. We analyzed performance of UDS by race, sex, age, and
hospital presentation (outside hospital [OSH] vs academic center).
The guidelines did not specify an age cutoff for young or
middle-aged patients; we selected age 55 for analysis purposes.
We also dichotomized the study time period into preguideline
and postguideline publication (online July 22, 2010) to assess if
guideline reiteration changed screening patterns.
Outcome measures included modified Rankin Scale score at
discharge and date, time, and cause of death for patients who died
during the hospitalization. We determined vital status via present-
day chart review and obituary query. We then performed
a National Death Index query for the vital status of all patients
for whom we still could not account.
Statistical methods. Patient characteristics were compared
between those screened and not by x2, Fisher exact, analysis of
variance, or Wilcoxon rank-sum tests where appropriate.
Modeling of UDS began with bivariate logistic regressions.
Each continuous candidate variable was assessed for linearity of
the logit, and those with evidence of nonlinearity were converted
to categorical variables. Variables with bivariate statistical
significance of #0.30 were eligible for inclusion in
a multivariable logistic model. A stepwise variable selection
method was utilized to find the best model, with a significance
level for remaining in the model of 0.05. Bivariate results are not
presented. b Coefficients from the resulting multivariable model
were used to calculate odds ratios (OR) and 95% confidence
intervals (CIs). Statistical analyses were performed with SAS
version 9.4 (SAS Institute, Cary, NC).
RESULTS We identified 610 patients with primary
ICH in 2009–2011; 379 (62.1%) were initially
evaluated at an OSH. Patients presenting initially to
OSH vs directly to the AHC were older (67.0 years vs
63.2 years, p 5 0.002) and less likely to be black
(6.9% vs 59.7%, p , 0.0001). Patients presenting
initially to an OSH also had a lower NIHSS (7 vs 12,
p 5 0.0002), lower systolic blood pressure (176.7 vs
189.9 mm Hg, p , 0.0001) and diastolic blood
pressure (96.1 vs 105.0 mm Hg, p , 0.0001), lower
Charlson score (1 [0–2] vs 1 [0–3], p5 0.003), lower
rate of tracheostomy (5.5% vs 10.4%, p 5 0.03),
and a shorter length of stay (7 days [4–12] vs 8 days
[5–16], p 5 0.004).
The baseline characteristics stratified by screening
status are shown in table 1. Overall, 142/610
(23.3%) patients had UDS performed, with 21 pos-
itive screens for cocaine and 3 for amphetamine, with
an overall yield of 16.9% (24/142). Patients screened
for DOA were younger; were more likely to be male,
black, and current smokers; were clinically more
severe (lower Glasgow Coma Scale [GCS] score, high-
er NIHSS, more intraventricular hemorrhage [IVH],
and a longer length of stay); and had higher systolic
and diastolic blood pressure than those not screened.
Of patients ,55 years of age, only 65/140 (46.4%)
were screened. There was a difference in screening
between nonblack and black patients ,55 years of
age (27/79 [34.2%] vs 38/61 [62.3%], p 5 0.0009).
Of the 74 patients ,55 years of age presenting to an
OSH, only 27 (36.5%) were screened: 10 at the OSH
only, 15 at the academic center only, and 2 at both
the OSH and the academic center. The proportion of
patients ,55 years of age screened who presented to
our centers initially was 38/66 (57.6%). The oldest
patient with a positive cocaine or amphetamine
screen was 63 years of age and the oldest screened
was 95 years of age. A total of 9 of 24 (37.5%) pa-
tients with a positive screen were older than 55 years,
and 18 of 24 (75%) were older than 45 years.
The best multivariable model (table 2) included
age group (p 5 0.0001), black race (p 5 0.4529),
first GCS score (p 5 0.0492), current smoking
(p , 0.0001), and the interaction between age group
and black race (p 5 0.0097), with an area under the
curve of 0.79 and no significant lack of fit (Hosmer-
Lemeshow goodness-of-fit: p 5 0.96). The frequen-
cies of those screened stratified by age group and race
are shown in table 3. The proportion screened
decreased in every ascending age group, but in all
age strata ,65 years, black patients were screened
more than nonblack patients. The most striking differ-
ences in screening between black and nonblack pa-
tients were in the 45–54 years of age stratum (OR
6.93, 95% CI 2.50–19.20, black vs nonblack, p 5
0.0002) and the 55–64 years of age stratum (OR 3.85,
95% CI 1.70–8.71, black vs nonblack, p 5 0.0012).
Among those screened, we also performed a sec-
ondary analysis of cocaine-positive and cocaine-
negative patients (table 4); to minimize potential
heterogeneity of the groups, we excluded the 3
amphetamine-positive patients from this analysis.
The cocaine-positive patients were more likely to be
black and to have a higher diastolic blood pressure at
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presentation. There was no difference in ICH loca-
tion or presence of IVH. There was no difference in
the rate of tracheostomy (2/21 vs 13/118, p 5 1.0),
percutaneous endoscopic gastrostomy tube (3/21 vs
27/118, p 5 0.57), discharge home (5/17 vs 22/91,
p 5 0.76), or decision for comfort care only (1/21 vs
12/118, p 5 0.69). With regard to outcomes, we did
not find a difference in discharge modified Rankin
Scale score (4 [3–4] vs 4 [3–5], p 5 0.66) or case-
fatality at any time point (inpatient [4/21 vs 27/118,
p 5 1.0], 30 days [4/21 vs 36/118, p 5 0.29], or
1 year [6/21 vs 49/118, p 5 0.26]).
Prior to guideline reiteration, 76/328 (23.2%)
patients were screened, compared to 66/282
(23.4%) after guideline reiteration (p 5 0.95). For
the ,55 years of age group, 42/74 (56.8%) were
screened before and 23/66 (34.9%) were screened
after (p 5 0.01).
DISCUSSION We found low overall rates of screen-
ing for DOA in our ICH cohort, with fewer than half
of patients ,55 years of age undergoing screening
and with opportunities for improvement at both
OSHs and academic centers. We also found that
younger age, black race, lower initial GCS score,
current smoking, and the interaction between age
group and black race were associated with screening.
The relationship between race and screening was
modified by age; black patients were screened more
frequently at all ages ,65 years, but the biggest
disparity was in middle age (age 45–64 years). We
did not find an improvement in rates of screening
after reiteration of the guidelines; in fact, in patients
,55 years of age, the proportion screened after
guideline reiteration was lower. (That screening of
young patients did not improve in the year and a half
following guideline reiteration is not surprising,
given well-documented lags in dissemination.12) In
contrast to a previous study of cocaine-associated
ICH, which reported higher frequency of nonlobar
locations, higher risk of IVH, and poorer
prognosis,3 we did not find differences in location,
intraventricular extension, or short-term outcomes
compared with cocaine-negative ICH. Though we
excluded the 3 amphetamine/methamphetamine-
positive patients from the analysis to minimize
potential heterogeneity, the pathophysiology of
cocaine and amphetamine/methamphetamine-
associated ICH is substantially similar. A previous
study of 25 patients with methamphetamine-
associated ICH also reported a higher frequency of
nonlobar locations, but did not find a difference in
rates of IVH or short-term outcomes.13 The reasons
for the differences in findings are not clear, but may
be secondary to small cohort size.
A previous study of urine drug screening in an
urban stroke center from 2005 to 2007 of more than
1,000 patients included 133 ICHs, of whom 57
(42.9%) patients were screened and 14 (24.6%) were
cocaine-positive. These investigators also found a high-
er rate of screening in black patients and men.14 Dis-
parities in screening may be partly related to a provider
expectation that the rate of sympathomimetic drug use
is higher in these particular subgroups. However, the
observed disparities in this study exceed the differences
seen in the 2011 National Survey on Drug Use and
Health (NSDUH). In that study, past-month illicit
drug use (age 12 years and older) was higher in black
or African American respondents (10%) than for white
(8.7%), Hispanic or Latino (8.4%), and Asian (3.8%)
respondents. Current illicit drug use was higher for
men (11.1%) than women (6.5%) for overall illicit
use, as well as for cocaine specifically (men 0.7% vs
women 0.4%). In addition, current illicit drug use was
higher in large metropolitan counties (9.2%) than in
nonmetropolitan, rural counties (5.7%).15 Further, use
of sympathomimetic drugs is not limited to young
patients. In fact, the 2011 NSDUH reported increas-
ing rates of overall illicit drug use in the age 50 to 59
years cohort—6.3% in 2011 compared to 2.7% in
2002.15 The authors note that this may be related to




(n 5 142) p Value
Age group, y, n (%) ,0.0001
<45 18 (3.8) 30 (21.1)
45–54 57 (12.2) 35 (24.7)
55–64 107 (22.9) 45 (31.7)
651 286 (61.1) 32 (22.5)
Black, n (%) 99 (21.2) 65 (45.8) ,0.0001
Female, n (%) 234 (50.0) 55 (38.7) 0.02
GCS, median (IQR) 14 (11–15) 14 (7–15) 0.004
NIHSS, median (IQR) 8 (3–17) 12 (4–25) 0.009
Charlson, median (IQR); max 1 (0–2); 8 1 (0–2); 6 0.01
ICH score, median (IQR) 1 (1–2) 2 (0–3) 0.16
ICH volume, median (IQR) 10.5 (2.5–27.0) 9.4 (2.5–24.8) 0.65
IVH presence, n (%) 208 (44.4) 78 (54.9) 0.03
IVH volume, median (IQR) 6.0 (2.2–16.4) 7.4 (2.2–16.4) 0.61
First SBP, mm Hg, mean (SD) 178.6 6 37.4 191.4 6 43.4 0.0007
First DBP, mm Hg, mean (SD) 96.6 6 25.7 108.8 6 26.3 ,0.0001
Current smoker, n (%)a 93 (20.1) 73 (55.7) ,0.0001
Anticoagulant use, n (%) 85 (18.2) 12 (8.5) 0.0056
Presentation at OSH, n (%) 314 (67.1) 65 (45.8) ,0.0001
Abbreviations: DBP 5 diastolic blood pressure; GCS 5 Glasgow Coma Scale; ICH 5 intra-
cerebral hemorrhage; IQR 5 interquartile range; IVH 5 intraventricular hemorrhage;
NIHSS 5 NIH Stroke Scale; OSH 5 outside hospital; SBP 5 systolic blood pressure.
aMissing smoking data for 16 patients (denominators: 463 screened, 131 not screened).
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the advancing age of the baby boom generation, who
have always had higher rates of illicit drug use.15 While
the disparities in screening may be driven by these
patterns of drug use, the result is a missed opportunity
for a comprehensive etiologic evaluation in all patients.
Not all illicit drugs associated with increased risk
of ICH will be identified on routine UDS. Standard
urine drug screening is a set of immunoassays that
evaluate for classes of drugs of abuse by structural sim-
ilarity to the reference drug. Urine screening for
cocaine is an immunoassay for benzoylecgonine,
a metabolite of cocaine that is formed rapidly after
exposure. This assay is typically highly sensitive and
specific for use of cocaine within the past 3 days.











Intercept 0.3772 0.5003 — 0.4509 —
Age group, y
<45 (referent) 0 0 — —
45–54 22.0355 0.5716 0.0001 0.0004 0.13 (0.04–0.40)
55–64 21.7293 0.4940 0.0005 0.18 (0.07–0.47)
651 22.0750 0.4673 ,0.0001 0.13 (0.05–0.31)
Race
Nonblack (referent) 0 0 — —
Black 0.5233 0.6973 0.4529 —
Age-race interaction
<45, White (referent) 0 0 — —
45–54, Black 1.4129 0.8687 0.0097 0.1038 4.11 (0.75–22.54)
55–64, Black 0.8251 0.8110 0.3089 2.28 (0.47–11.19)
651, Black 21.0381 0.9005 0.2490 0.35 (0.06–2.07)
First GCS 20.0550 0.0280 0.0492 0.0492 0.95 (0.90–1.00)
Current smoker
No (referent) 0 0 — —
Yes 1.2885 0.2475 ,0.0001 ,0.0001 3.63 (2.23–5.89)
Abbreviations: CI 5 confidence interval; GCS 5 Glasgow Coma Scale.
Area under the curve 5 0.79.
Table 3 Screening by race within age strata
Overall Not screened Screened p Value Odds ratio (95% CI)
Under 45 years old, n (%) n 5 48 18 (37.5) 30 (62.5)
Black 19 (39.6) 6 (31.6) 13 (68.4) 0.4529 1.69 (0.43–6.62)
Nonblack 29 (60.4) 12 (41.4) 17 (58.6) (referent)
45–54 years old, n (%) n 5 92 57 (62.0) 35 (38.0)
Black 42 (45.7) 17 (40.5) 25 (59.5) 0.0002 6.93 (2.50–19.20)
Nonblack 50 (54.3) 40 (80.0) 10 (20.0) (referent)
55–64 years old, n (%) n 5 152 107 (70.4) 45 (29.6)
Black 50 (32.9) 27 (54.0) 23 (46.0) 0.0012 3.85 (1.70–8.71)
Nonblack 102 (67.1) 80 (78.4) 22 (21.6) (referent)
651 years old, n (%) n 5 318 286 (89.9) 32 (10.1)
Black 53 (16.7) 49 (92.5) 4 (7.5) 0.3654 0.60 (0.20–1.82)
Nonblack 265 (83.3) 237 (89.4) 28 (10.6) (referent)
Abbreviation: CI 5 confidence interval.
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Urine screening for amphetamines is less sensitive for
substances that would be typically regarded as am-
phetamines, specifically a rate of detection for meth-
ylenedioxymethamphetamine that is 50% lower than
for amphetamine and methamphetamine. It is also
less specific in that there is a large number of over-
the-counter and prescription drugs that can cross-
react with this assay.16 More importantly, neither
the cocaine nor the amphetamines assay will reliably
detect some of the emerging DOA with sympatho-
mimetic effects. This includes both cathinone (Khat,
from the plant Catha edulis) and synthetic cathinones
(e.g., bath salts) within the phenethylamine category
of DOA. In addition, the standard marijuana immu-
noassay will be negative in patients with synthetic
cannabinoid (e.g., K2/Spice) use. ICH has been re-
ported in association with Khat,17 Spice,18 and the
stimulant1,3-dimethylethylamine (DMAA).19 None
of these substances would produce a positive result
on a standard UDS. This is especially relevant because
Indiana Poison Center data, which record real-time
data on exposures for the same geographic area as the
INPC data in this study, show that there was a peak of
reported new sympathomimetics and synthetic canna-
binoid use in central Indiana in 2011 (personal com-
munication with James Mowry, PharmD, September
25, 2015; see appendix e-1 at Neurology.org).
Strengths of this work include a large and well-
characterized ICH cohort, data on UDS screening
from OSHs, inclusion of a preguideline and postgui-
deline publication timeframe, and 1-year outcomes
data. Limitations of our study include its retrospec-
tive cohort design that is academic center–based and
not population-based, so the findings may not be
applicable to all patient populations. We reviewed
all available records, but it is possible that some
OSH records were not included in the transfer re-
cords. Detailed social history was not available, so
we cannot draw conclusions about the effect on
screening of a focused drug abuse history. The
UDS results are limited by the immunoassay
technique, as discussed above, and no confirmatory
testing was performed to exclude cross-reactivity
with non-DOA substances. The secondary analysis
pertaining to cocaine use is limited to a relatively
small sample size. There may be other factors for
which we cannot account that played a role in select-
ing patients for screening. Finally, these data are
from 2009 to 2011, and screening patterns might
have changed.
There are several important implications of this
work for the care of ICH patients. Given the dispar-
ities in screening and incongruence between patient
behavior and physician perceptions noted in this
study and others,14,20 we advocate for DOA screening
in most ICH patients presenting in the appropriate
timeframe. While an analysis of the cost-effectiveness
of screening is beyond the scope of the present work,
we found a yield of at least 4% in our ICH cohort (if
all unscreened patients were in fact negative), which is
similar to a previous report.21 Screening for DOA is
also relatively inexpensive (see below) compared to
other common investigations in stroke patients.
Screening should include an immunoassay for
cocaine and amphetamines, as well as a targeted social
history. While there may be other indications to per-
form a complete UDS, sympathomimetics are the
drugs of interest in terms of potential ICH etiology.
At our institution, the price of a routine UDS panel is
$670, while selected testing of sympathomimetics is
$192 (personal communication, Jim McGown, Indi-
ana University Health Laboratory, May 23, 2016), so
unless the full panel is otherwise warranted, limited
testing is preferred. The targeted social history should
be performed at a time when the patient or family is




(n 5 118) p Value
Age group, y, n (%) 0.01
<45 4 (19.0) 24 (20.3)
45–54 9 (42.9) 26 (22.0)
55–64 8 (38.1) 36 (30.5)
651 0 (0) 32 (27.1)
Black, n (%) 20 (95.2) 45 (38.1) ,0.0001
Female, n (%) 8 (38.1) 47 (39.8) 0.88
GCS, median (IQR) 13 (9.5–15) 13.5 (6–15) 0.67
NIHSS, median (IQR) 12 (7–18) 12.5 (3–27) 0.99
Charlson, median (IQR) 1 (0–2) [max: 5] 1 (0–2) [max: 6] 0.21
ICH score, median (IQR) 2 (1–2) 2 (0–3) 0.80
ICH volume, mL, median (IQR) 9.0 (1.9–26.3) 10.0 (2.9–24.6) 0.68
IVH presence, n (%) 12 (57.1) 65 (55.1) 0.86
IVH volume, mL, median (IQR) 10.0 (3.7–16.4) 7.4 (2.2–30.0) 0.65
First SBP, mm Hg, mean (SD) 206.7 6 32.4 189.3 6 43.4 0.09
First DBP, mm Hg, mean (SD) 124.1 6 21.1 106.8 6 26.2 0.006
Current smoker, n (%)a 15 (83.3) 55 (50.0) 0.008
Anticoagulant use, n (%) 1 (4.8) 11 (9.3) 0.69
OSH, n (%) 2 (9.5) 60 (50.9) 0.0004
ICH location, n (%) 0.49
Deep 14 (66.7) 65 (55.1)
Lobar 3 (14.3) 35 (29.7)
Brainstem 2 (9.5) 10 (8.5)
Cerebellar 2 (9.5) 8 (6.8)
Abbreviations: DBP 5 diastolic blood pressure; GCS 5 Glasgow Coma Scale; ICH 5 intra-
cerebral hemorrhage; IQR 5 interquartile range; IVH 5 intraventricular hemorrhage;
NIHSS 5 NIH Stroke Scale; OSH 5 outside hospital; SBP 5 systolic blood pressure.
Three amphetamine-positive patients not included.
aMissing smoking data for 11 patients (denominators: 18 positive, 110 negative).
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capable of a thoughtful history and include language
directed at use of any sympathomimetic, which may
be accomplished by the interviewer mentioning bath
salts and K2/Spice (in addition to cocaine and am-
phetamines) as examples of DOA. The interview
should also include an open-ended question about
any other substance use in order to identify the next
category of emerging substances.
We found marked disparities in sympathomimetic
DOA screening and identified a substantial opportu-
nity for screening improvements. Improved identifi-
cation of sympathomimetic exposure may improve
ICH etiologic classification with the potential to
influence therapeutic decision-making and prognosis
counseling. Future investigations should include
a prospective assessment of DOA across different geo-
graphic settings to better understand patterns of use
and their relation to ICH and development of larger
cohorts of sympathomimetic-related ICH to more
fully evaluate the effect of these drugs on patient out-
comes. Future studies should also examine trends in
screening several years after guideline publication to
assess degree of implementation.
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